INNOGEN-B completes first patient dosing in Phase Ib adolescent-obesity trial for Efsubaglutide Alfa

Bulletin Express07-28

Guangzhou Innogen Pharmaceutical Group Co., Ltd. (“INNOGEN-B”) reported that the first adolescent patient has been enrolled and dosed in the Phase Ib clinical trial of Efsubaglutide Alfa for obesity treatment, with the procedure completed on 28 July 2026.

The company noted that no safety issues or adverse reactions were observed during the immediate post-dosing observation period.

Management originally targeted July 2026 for trial initiation, as disclosed on 22 June 2026. The on-schedule first dosing marks a key operational milestone in the programme’s early-stage clinical development.

INNOGEN-B indicated that further updates will be provided in line with applicable regulatory requirements, while reiterating that successful development and commercialisation of Efsubaglutide Alfa are not guaranteed.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1168740565?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-28 20:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1168740565","market":"hk","top_or_hot":-1,"title":"INNOGEN-B completes first patient dosing in Phase Ib adolescent-obesity trial for Efsubaglutide Alfa","media":"Bulletin Express","content":"<p>Guangzhou Innogen Pharmaceutical Group Co., Ltd. (“INNOGEN-B”) reported that the first adolescent patient has been enrolled and dosed in the Phase Ib clinical trial of Efsubaglutide Alfa for obesity treatment, with the procedure completed on 28 July 2026.</p>\n<p>The company noted that no safety issues or adverse reactions were observed during the immediate post-dosing observation period.</p>\n<p>Management originally targeted July 2026 for trial initiation, as disclosed on 22 June 2026. The on-schedule first dosing marks a key operational milestone in the programme’s early-stage clinical development.</p>\n<p>INNOGEN-B indicated that further updates will be provided in line with applicable regulatory requirements, while reiterating that successful development and commercialisation of Efsubaglutide Alfa are not guaranteed.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>INNOGEN-B completes first patient dosing in Phase Ib adolescent-obesity trial for Efsubaglutide Alfa</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nINNOGEN-B completes first patient dosing in Phase Ib adolescent-obesity trial for Efsubaglutide Alfa\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-07-28 20:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Guangzhou Innogen Pharmaceutical Group Co., Ltd. (“INNOGEN-B”) reported that the first adolescent patient has been enrolled and dosed in the Phase Ib clinical trial of Efsubaglutide Alfa for obesity treatment, with the procedure completed on 28 July 2026.</p>\n<p>The company noted that no safety issues or adverse reactions were observed during the immediate post-dosing observation period.</p>\n<p>Management originally targeted July 2026 for trial initiation, as disclosed on 22 June 2026. The on-schedule first dosing marks a key operational milestone in the programme’s early-stage clinical development.</p>\n<p>INNOGEN-B indicated that further updates will be provided in line with applicable regulatory requirements, while reiterating that successful development and commercialisation of Efsubaglutide Alfa are not guaranteed.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02591","symbol_name":"银诺医药-B","start_time":0,"source_url":"","article_id":"1168740565","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1168740565","pubTimestamp":1785242819,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Guangzhou Innogen Pharmaceutical Group Co., Ltd. (“INNOGEN-B”) reported that the first adolescent patient has been enrolled and dosed in the Phase Ib clinical trial of Efsubaglutide Alfa for obesity...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02591":"银诺医药-B"},"translate_title":"INNOGEN-B 完成Efsubaglutide Alfa Ib 期青少年肥胖试验的首例患者给药","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02591":1},"content_text":"Guangzhou Innogen Pharmaceutical Group Co., Ltd. (“INNOGEN-B”) reported that the first adolescent patient has been enrolled and dosed in the Phase Ib clinical trial of Efsubaglutide Alfa for obesity treatment, with the procedure completed on 28 July 2026.\nThe company noted that no safety issues or adverse reactions were observed during the immediate post-dosing observation period.\nManagement originally targeted July 2026 for trial initiation, as disclosed on 22 June 2026. The on-schedule first dosing marks a key operational milestone in the programme’s early-stage clinical development.\nINNOGEN-B indicated that further updates will be provided in line with applicable regulatory requirements, while reiterating that successful development and commercialisation of Efsubaglutide Alfa are not guaranteed.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1168740565","isCrawlerRequest":true}